Literature DB >> 1416407

Diagnosis of Pneumocystis carinii pneumonia by multiple lobe, site-directed bronchoalveolar lavage with immunofluorescent monoclonal antibody staining in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis.

S J Levine1, D Kennedy, J H Shelhamer, A Kovacs, I M Feuerstein, V J Gill, F Stock, D Solomon, C T Boylen, H Masur.   

Abstract

The yields of both induced sputum examination and bronchoalveolar lavage (BAL) have been reported to be decreased for breakthrough episodes of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients receiving aerosolized pentamidine chemoprophylaxis. This study assessed whether the yield of a single middle or lower lobe BAL could be increased by the utilization of two techniques: (1) indirect immunofluorescent staining with a combination of two murine monoclonal anti-Pneumocystis antibodies in addition to routine toluidine blue O and cytopathologic staining, and (2) the performance of multiple lobe, site-directed BAL (i.e., both upper lobe and middle or lower lobe lavage, including the lobe with the greatest radiographic abnormality). Results of 252 fiberoptic bronchoscopies performed at the National Institutes of Health and the Los Angeles County-University of Southern California Medical Center were analyzed. P. carinii pneumonia was documented in 21 episodes in patients who did not receive prior anti-Pneumocystis chemoprophylaxis and in 41 episodes in patients who received aerosolized pentamidine. Monoclonal antibody staining and multiple lobe, site-directed BAL resulted in similar diagnostic yields for P. carinii in the nonprophylaxis (100%) and aerosolized pentamidine (98%) groups. If BAL had been performed without monoclonal antibody staining and multiple lobe, site-directed lavage, then the yield would have decreased to 95% in the nonprophylaxis group and to 80% in the aerosolized pentamidine group.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416407     DOI: 10.1164/ajrccm/146.4.838

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

Review 1.  The pulmonary physician in critical care 1: pulmonary investigations for acute respiratory failure.

Authors:  J Dakin; M Griffiths
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Elevated serum beta-D-glucan levels in immunocompromised children with clinical suspicion for Pneumocystis jirovecii pneumonia.

Authors:  Blanca E Gonzalez; Luis A Faverio; Francisco M Marty; Craig MacArthur; Robin B Churchill
Journal:  Clin Vaccine Immunol       Date:  2011-05-04

3.  Use of bronchoscopy in the diagnosis of infection in the immunocompromised host.

Authors:  R P Baughman
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

4.  Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR.

Authors:  M Rabodonirina; D Raffenot; L Cotte; A Boibieux; M Mayençon; G Bayle; F Persat; F Rabatel; C Trepo; D Peyramond; M A Piens
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

Review 5.  Pulmonary Infections in Immunocompromised Hosts: Clinical.

Authors:  Cristina Vazquez Guillamet; Joe Le Hsu; Gundeep Dhillon; Rodrigo Vazquez Guillamet
Journal:  J Thorac Imaging       Date:  2018-09       Impact factor: 3.000

Review 6.  Clinical review: Respiratory failure in HIV-infected patients--a changing picture.

Authors:  Putul Sarkar; Husham F Rasheed
Journal:  Crit Care       Date:  2013-06-14       Impact factor: 9.097

Review 7.  Pneumocystis jirovecii detection in asymptomatic patients: what does its natural history tell us?

Authors:  Alexandre Alanio; Stéphane Bretagne
Journal:  F1000Res       Date:  2017-05-23

8.  A novel diagnostic approach for Pneumocystis jirovecii pneumonia using fine-needle aspiration, electromagnetic navigational bronchoscopy and rapid on-site evaluation.

Authors:  Farnaz Houshmand; Fatima Zahra Aly; Mark Rollin Bowling
Journal:  Ann Thorac Med       Date:  2019 Oct-Dec       Impact factor: 2.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.